• Twitter
  • Jobs
ProCURE oncology
  • HOME
  • ABOUT US
  • RESEARCH GROUP
    • Molleví’s Lab
    • Antolin’s Lab
    • Alemany’s & Piulats’s lab
    • Martínez-Balibrea’s Lab
    • Aytes’s Lab
    • Belver’s Lab
    • Pujana’s Lab
    • Menendez’s Lab
    • Sureda’s & Farre’s Lab
    • Casanovas’s Lab
    • Viñals’s lab
  • INNOVATION
  • NEWS
  • CONTACT
  • Menu Menu

DNA double-strand break-capturing nuclear envelope tubules drive DNA repair

17 de April de 2024
Nat Struct Mol Biol. 2024 Apr 17. doi: 10.1038/s41594-024-01286-7.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2024-04-17 10:00:002024-04-17 10:00:00DNA double-strand break-capturing nuclear envelope tubules drive DNA repair

Large-scale genome-wide association study of 398,238 women unveils seven novel loci associated with high-grade serous epithelial ovarian cancer risk

18 de March de 2024
medRxiv [Preprint]. 2024 Mar 4:2024.02.29.24303243. doi: 10.1101/2024.02.29.24303243.ABSTRACTBACKGROUND:…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2024-03-18 10:00:002024-03-18 10:00:00Large-scale genome-wide association study of 398,238 women unveils seven novel loci associated with high-grade serous epithelial ovarian cancer risk

Identification of differential biological activity and synergy between the PARP inhibitor rucaparib and its major metabolite

9 de February de 2024
Cell Chem Biol. 2024 Feb 6:S2451-9456(24)00043-6. doi: 10.1016/j.chembiol.2024.01.007.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2024-02-09 11:00:002024-02-09 11:00:00Identification of differential biological activity and synergy between the PARP inhibitor rucaparib and its major metabolite

Biological basis of extensive pleiotropy between blood traits and cancer risk

3 de February de 2024
Genome Med. 2024 Feb 2;16(1):21. doi: 10.1186/s13073-024-01294-8.ABSTRACTBACKGROUND:…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2024-02-03 11:00:002024-02-03 11:00:00Biological basis of extensive pleiotropy between blood traits and cancer risk

Topoisomerase 1 Inhibition in MYC-Driven Cancer Promotes Aberrant R-Loop Accumulation to Induce Synthetic Lethality

21 de November de 2023
Cancer Res. 2023 Nov 21:OF1-OF15. doi: 10.1158/0008-5472.CAN-22-2948.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2023-11-21 11:00:002023-11-21 11:00:00Topoisomerase 1 Inhibition in MYC-Driven Cancer Promotes Aberrant R-Loop Accumulation to Induce Synthetic Lethality

Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineages

26 de October de 2023
Cell Rep. 2023 Oct 25;42(11):113382. doi: 10.1016/j.celrep.2023.113382.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-10-26 10:00:002023-10-26 10:00:00Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineages

Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineages

17 de October de 2023
Cell Rep. 2023 Oct 31;42(10):113256. doi: 10.1016/j.celrep.2023.113256.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-10-17 10:00:002023-10-17 10:00:00Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineages

RNF8 ubiquitylation of XRN2 facilitates R-loop resolution and restrains genomic instability in BRCA1 mutant cells

12 de September de 2023
Nucleic Acids Res. 2023 Oct 27;51(19):10484-10505. doi: 10.1093/nar/gkad733.ABSTRACTBreast…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-09-12 10:00:002023-09-12 10:00:00RNF8 ubiquitylation of XRN2 facilitates R-loop resolution and restrains genomic instability in BRCA1 mutant cells

PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants

12 de May de 2023
NPJ Breast Cancer. 2023 May 12;9(1):37. doi: 10.1038/s41523-023-00546-x.ABSTRACTWe…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-05-12 10:00:002023-05-12 10:00:00PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants

Excessive transcription-replication conflicts are a vulnerability of BRCA1-mutant cancers

17 de March de 2023
Nucleic Acids Res. 2023 May 22;51(9):4341-4362. doi: 10.1093/nar/gkad172.ABSTRACTBRCA1…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-03-17 10:00:002023-03-17 10:00:00Excessive transcription-replication conflicts are a vulnerability of BRCA1-mutant cancers

Loss of Epigenetic Regulation Disrupts Lineage Integrity, Induces Aberrant Alveogenesis, and Promotes Breast Cancer

15 de September de 2022
Cancer Discov. 2022 Dec 2;12(12):2930-2953. doi: 10.1158/2159-8290.CD-21-0865.ABSTRACTSystematically…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2022-09-15 10:00:002022-09-15 10:00:00Loss of Epigenetic Regulation Disrupts Lineage Integrity, Induces Aberrant Alveogenesis, and Promotes Breast Cancer

A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors

5 de May de 2022
Mol Cancer Ther. 2022 Jul 5;21(7):1246-1258. doi: 10.1158/1535-7163.MCT-21-0947.ABSTRACTMalignant…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2022-05-05 10:00:002022-05-05 10:00:00A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors
Page 2 of 10‹1234›»

Filter by categories

  • Alemany’s & Piulats’s lab (131)
  • Antolin's lab (36)
  • Aytes's Lab (24)
  • Belver's Lab (25)
  • Casanovas's Lab (77)
  • Martínez-Balibrea's Lab (43)
  • Menendez's Lab (121)
  • Molleví's Lab (35)
  • Pujana's Lab (110)
  • Sureda's & Farre's Lab (259)
  • Viñals's lab (111)

Twitter

Tweets by ProcureICO
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

© Copyright - Edisenius
  • Privacy Policy
  • Cookie Policy
  • Legal Notice
Scroll to top
Manage cookie consent
To offer the best experiences, we use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent, or withdrawal of consent, may adversely affect certain features and functions.
Functional Always active
Storage or technical access is strictly necessary for the legitimate purpose of allowing the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. Storage or technical access that is used exclusively for anonymous statistical purposes. Without a requirement, voluntary compliance by your Internet service provider, or additional records from a third party, information stored or retrieved solely for this purpose cannot be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles to send advertising, or to track the user on a website or several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
See preferences
{title} {title} {title}